AtLAS: DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery
Study Details
Study Description
Brief Summary
To determine patient preference and treatment outcomes with an intracanalicular dexamethasone (0.4mg) insert compared to standard steroid drop regimen in the contralateral eye following bilateral LASIK surgery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to investigate the outcomes of patients undergoing bilateral LASIK surgery with the treatment of a dexamethasone intracanalicular insert compared to standard of care topical prednisolone. All eyes will receive treatment. Additionally, all eyes will receive topical moxifloxacin QID for 1 week.
Twenty patient eyes undergoing bilateral LASIK surgery will be randomized to receive either Dextenza (Group A) OR standard of care prednisolone acetate 1% QID for 1 week, BID for 1 week (Group B). The contralateral eye will receive treatment with either DEXTENZA or topical prednisolone as a comparator based on randomization of first eye to Group A or Group B. Post-operative evaluations will be performed on Day 1, Day 7, and Month 1 following surgery.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group A Dextenza |
Drug: Dextenza 0.4Mg Ophthalmic Insert
The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
| Active Comparator: Group B Topical Prednisolone |
Drug: Topical Prednisolone
Standard of care topical drop treatment
|
Outcome Measures
Primary Outcome Measures
- Patient Preference [Through Month 1 (Day 28 +/- 3 days)]
As measured by COMTOL adapted survey.
- Patient Comfort [Through Month 1 (Day 28 +/- 3 days)]
As measured by SPEED Questionnaire.
Secondary Outcome Measures
- Ocular Surface Health [Through Month 1 (Day 28 +/- 3 days)]
As measured by corneal staining.
- Visual Outcomes [Through Month 1 (Day 28 +/- 3 days)]
As measured by uncorrected Visual Acuity.
- Ocular Pain [Through Month 1 (Day 28 +/- 3 days)]
As measured by Ocular Pain Assessment.
Other Outcome Measures
- Safety Endpoints [Through Month 1 (Day 28 +/- 3 days)]
As measured by intraocular pressure increase of 10 mm Hg or greater from baseline.
- Safety Endpoints [Through Month 1 (Day 28 +/- 3 days)]
As measured by proportion of eyes rescued with additional topical prednisolone treatment or increased frequency of dosing.
- Safety Endpoints [Through Month 1 (Day 28 +/- 3 days)]
As measured by occurrence of adverse events.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Any adult patient who is planned to undergo bilateral LASIK surgery.
-
Refractive error between the 2 eyes of 2 Diopters or less
-
Willing and able to comply with clinic visits and study related procedures
-
Willing and able to sign the informed consent form
Exclusion Criteria:
-
Patients under the age of 18.
-
Patients who choose to have monovision after LASIK
-
Patients with corneal pathology that may interfere with LASIK outcomes
-
Patients who are pregnant (must be ruled out in women of child-bearing age with pregnancy test).
-
Active infectious ocular or systemic disease.
-
Patients with active infectious ocular or extraocular disease.
-
Patients actively treated with local or systemic immunosuppression including systemic corticosteroids.
-
Patients with known hypersensitivity to Dexamethasone.
-
Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator.
-
Patients with a history of ocular inflammation or macular edema.
-
Patients with allergy or inability to receive topical antibiotic.
-
Patients on systemic non-steroidal anti-inflammatory drugs (NSAID) greater than 1,200 mg/day
-
Patients with a corticosteroid implant (i.e. Ozurdex).
-
Active or history of chronic or recurrent inflammatory eye disease in either eye
-
Ocular pain in either eye
-
Proliferative diabetic retinopathy in either eye
-
Significant macular pathology detected on macular optical coherence tomography evaluation at the screening visit in either eye
-
Laser or incisional ocular surgery during the study period and 6 months prior in either eye
-
History of cauterization of the punctum
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Vance Thompson Vision ND | W. Fargo | North Dakota | United States | 58078 |
Sponsors and Collaborators
- Vance Thompson Vision
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ATLAS2020